Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb 29:10:22-6.
doi: 10.2174/1874364101610010022. eCollection 2016.

Coats' Disease: Very Long-Term Outcome After Early Stage Conventional Treatment

Salvatore Perrone  1 , Alberto Rossetti  1 , Patrick Sportiello  1 , Pierfrancesco Mirabelli  1 , Pierangela Cimatti  1 , Daniele Doro  1
Affiliations

Coats' Disease: Very Long-Term Outcome After Early Stage Conventional Treatment

Salvatore Perrone et al. Open Ophthalmol J. .

Abstract

Purpose: To report on the outcome of conventional therapy in patients with Coats' disease.

Methods: Retrospective analysis of the charts of thirteen patients with Coats' disease.

Results: Mean age of 9 male (70%) and 4 female (30%) patients was 17.7 (range, 5-33) years; one female had bilateral disease. Eleven eyes with retinal telangiectasia and exudation were treated with argon laser photocoagulation alone or photocoagulation associated with cryotherapy; the mean follow up was 32.5 (range,17-41) years. In four eyes without foveal involvement (stage 2a) the mean presenting visual acuity (VA) remained at 0.8 or improved, whereas poor VA in seven stage 2b eyes deteriorated minimally over time. In one and two of the three eyes with total retinal detachment, phthisis or neovascular glaucoma ensued.

Conclusion: About three decades after conventional treatment of Coats' disease stage 2a, treated eyes maintained good VA, and stage 2b eyes did not progress to advanced stages.

Keywords: Coats' disease; exudative retinopathy; neovascular glaucoma; retinal detachment; telangiectasia.

PubMed Disclaimer

References

    1. Shields J.A., Shields C.L., Honavar S.G., Demirci H. Clinical variations and complications of Coats disease in 150 cases: the 2000 Sanford Gifford Memorial Lecture. Am. J. Ophthalmol. 2001;131(5):561–571. doi: 10.1016/S0002-9394(00)00883-7. - DOI - PubMed
    1. Spitznas M., Joussen F., Wessing A., Meyer-Schwickerath G. Coat’s disease. An epidemiologic and Fluorescein angiographic study. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol. 1975;195(4):241–250. doi: 10.1007/BF00414937. - DOI - PubMed
    1. Silodor S.W., Augsburger J.J., Shields J.A., Tasman W. Natural history and management of advanced Coats’ disease. Ophthalmic Surg. 1988;19(2):89–93. - PubMed
    1. Char D.H. Coats’ syndrome: long term follow up. Br. J. Ophthalmol. 2000;84(1):37–39. doi: 10.1136/bjo.84.1.37. - DOI - PMC - PubMed
    1. Shields J.A., Shields C.L., Honavar S.G., Demirci H., Cater J. Classification and management of Coats disease: the 2000 Proctor Lecture. Am. J. Ophthalmol. 2001;131(5):572–583. doi: 10.1016/S0002-9394(01)00896-0. - DOI - PubMed

LinkOut - more resources